Transmedics Group Inc (NASDAQ: TMDX) has a higher price-to-earnings ratio of 94.44x compared to its average ratio. TMDX has 36-month beta value of 2.08. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 1 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for TMDX is 32.58M, and currently, short sellers hold a 24.81% ratio of that float. The average trading volume of TMDX on June 18, 2025 was 1.04M shares.
TMDX) stock’s latest price update
The stock of Transmedics Group Inc (NASDAQ: TMDX) has decreased by -5.66 when compared to last closing price of 136.20.Despite this, the company has seen a loss of -10.07% in its stock price over the last five trading days. accessnewswire.com reported 2025-06-15 that NEW YORK CITY, NY / ACCESS Newswire / June 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. (“TransMedics” or “the Company”) (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/TMDX.
TMDX’s Market Performance
Transmedics Group Inc (TMDX) has seen a -10.07% fall in stock performance for the week, with a 5.23% gain in the past month and a 82.70% surge in the past quarter. The volatility ratio for the week is 1.99%, and the volatility levels for the past 30 days are at 2.17% for TMDX.. The simple moving average for the past 20 days is -3.16% for TMDX’s stock, with a 33.93% simple moving average for the past 200 days.
Analysts’ Opinion of TMDX
Many brokerage firms have already submitted their reports for TMDX stocks, with JP Morgan repeating the rating for TMDX by listing it as a “Neutral.” The predicted price for TMDX in the upcoming period, according to JP Morgan is $75 based on the research report published on December 17, 2024 of the previous year 2024.
Oppenheimer gave a rating of “Outperform” to TMDX, setting the target price at $125 in the report published on October 29th of the previous year.
TMDX Trading at 15.65% from the 50-Day Moving Average
After a stumble in the market that brought TMDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.56% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TMDX starting from Ranganath Anil P., who sale 686 shares at the price of $139.80 back on Jun 09 ’25. After this action, Ranganath Anil P. now owns 13,955 shares of Transmedics Group Inc, valued at $95,903 using the latest closing price.
Basile Edward M, the Director of Transmedics Group Inc, sale 5,000 shares at $126.45 during a trade that took place back on May 27 ’25, which means that Basile Edward M is holding 2,866 shares at $632,250 based on the most recent closing price.
Stock Fundamentals for TMDX
Current profitability levels for the company are sitting at:
- 0.11 for the present operating margin
- 0.59 for the gross margin
The net margin for Transmedics Group Inc stands at 0.1. The total capital return value is set at 0.07. Equity return is now at value 22.99, with 6.27 for asset returns.
Based on Transmedics Group Inc (TMDX), the company’s capital structure generated 0.66 points at debt to capital in total, while cash flow to debt ratio is standing at 0.1. The debt to equity ratio resting at 1.95. The interest coverage ratio of the stock is 4.93.
Currently, EBITDA for the company is 69.95 million with net debt to EBITDA at 2.52. When we switch over and look at the enterprise to sales, we see a ratio of 9.31. The receivables turnover for the company is 3.44for trailing twelve months and the total asset turnover is 0.58. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.10.
Conclusion
To put it simply, Transmedics Group Inc (TMDX) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
